Generic Zithromax ( Azithromycin )

Buy Generic Zithromax (Azithromycin) without prescription in Canada

In our Canadian pharmacy, you can buy Zithromax (Azithromycin) without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Zithromax (azithromycin dihydrate) is a macrolide antibiotic of the azalide subclass used to treat a wide variety of mild to moderate bacterial infections, including respiratory tract infections, skin infections, ear infections, and sexually transmitted infections. It works by binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis and preventing bacterial growth. Because of its long tissue half‑life and extensive distribution into cells, azithromycin can be administered in short courses or as a single dose for certain infections, making it a convenient treatment option.

Usual adult dose: For most respiratory and skin infections, the recommended dose is 500 mg on the first day, followed by 250 mg once daily on days 2 through 5, for a total dose of 1.5 grams. For acute bacterial sinusitis or acute exacerbations of chronic obstructive pulmonary disease, 500 mg once daily for 3 days may be used. For chlamydial genitourinary infections, a single 1 gram (1000 mg) oral dose is given. For gonococcal urethritis and cervicitis, a single 2 gram (2000 mg) dose is recommended. The 100 mg/5 mL oral suspension is used for children and adults who cannot swallow tablets; the dose is weight‑based (usually 10 mg/kg once daily).

Dosage form: Oral tablets: 250 mg, 500 mg, and 600 mg. Powder for oral suspension: 100 mg/5 mL and 200 mg/5 mL after reconstitution. Single‑dose 1 gram (1000 mg) sachet for suspension.

Onset of action: Azithromycin is rapidly absorbed, with peak plasma concentrations achieved 2 to 3 hours after an oral dose. Clinical improvement is typically seen within 48 to 72 hours, although the full course of therapy must be completed even if symptoms resolve sooner.

Duration of action: The elimination half‑life of azithromycin is approximately 68 hours, reflecting its extensive tissue distribution and slow release. This long half‑life allows once‑daily dosing and short (3‑ to 5‑day) courses of therapy, with therapeutic concentrations persisting in tissues for up to 10 days after the last dose.

Alcohol recommendation: Alcohol consumption does not directly interfere with the antibacterial action of Zithromax. However, alcohol should be limited during treatment because it can worsen gastrointestinal side effects such as nausea and diarrhoea, impair the immune response, and dehydrate the body. Patients with significant alcohol use should be counselled about the rare risk of hepatotoxicity associated with azithromycin.

Most common side effects: Diarrhoea or loose stools (4‑5%), nausea (3‑4%), abdominal pain (2‑3%), and vomiting (1%). Other common effects include headache, dizziness, and skin rash. Rare but serious side effects include QT interval prolongation and torsade de pointes, hepatotoxicity, Clostridioides difficile‑associated diarrhoea, and serious allergic reactions including angioedema, Stevens‑Johnson syndrome, and toxic epidermal necrolysis.

Would you like to try Zithromax (Azithromycin) without a prescription?

General Information about Zithromax (Azithromycin)

• INN (International Nonproprietary Name): Azithromycin (as azithromycin dihydrate).
• Brand names available in Canada: Zithromax® (Pfizer Canada ULC) is the original brand‑name product. Widely available generic versions include APO‑Azithromycin (Apotex Inc.), TEVA‑Azithromycin (Teva Canada Limited), Sandoz Azithromycin (Sandoz Canada Inc.), PMS‑Azithromycin (Pharmascience Inc.), JAMP‑Azithromycin (JAMP Pharma Corporation), and azithromycin tablets and suspension from several other generic manufacturers.
• ATC code: J01FA10 (azithromycin; macrolides, lincosamides and streptogramins).
• Dosage forms and strengths: Oral tablets: 250 mg and 600 mg (as azithromycin dihydrate). Powder for oral suspension: 100 mg/5 mL and 200 mg/5 mL after reconstitution. Single‑dose 1 gram (1000 mg) oral suspension sachet. A 500 mg immediate‑release tablet is also available internationally and supplied by our pharmacy.
• Manufacturers in Canada: Pfizer Canada ULC (Zithromax), Apotex Inc., Teva Canada Limited, Sandoz Canada Inc., Pharmascience Inc., JAMP Pharma Corporation, and other generic manufacturers.
• Registration status in Canada: Approved by Health Canada. First marketed in Canada in 1992 (Zithromax). Multiple generic formulations are currently marketed and available by prescription. DINs: 02223724 (Zithromax powder for suspension 200 mg/5 mL), 02545977 (generic azithromycin 600 mg tablet), and many others.
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act. Available only with a valid prescription from a licensed Canadian healthcare professional.

Mechanism of Action and Pharmacology

Azithromycin is a semisynthetic macrolide antibiotic of the azalide subclass, structurally derived from erythromycin by the insertion of a methyl‑substituted nitrogen atom into the 14‑membered lactone ring. This modification creates a 15‑membered ring, which improves acid stability, oral absorption, and tissue penetration compared with erythromycin. Azithromycin exerts its antibacterial effect by binding to the 23S rRNA of the 50S subunit of the bacterial ribosome, thereby blocking the translocation step of protein synthesis and inhibiting bacterial growth. Depending on the concentration and susceptibility of the organism, azithromycin can be bacteriostatic or bactericidal. The antibacterial activity of azithromycin is pH‑related and appears to be reduced with decreasing pH; however, the extensive distribution of the drug into tissues and cells may be relevant to clinical activity.

Following oral administration, azithromycin is rapidly absorbed, with peak plasma concentrations achieved within 2 to 3 hours. The absolute oral bioavailability of a 250 mg tablet is approximately 38%. Food reduces the absorption of immediate‑release tablets, so they should be taken on an empty stomach; the tablets can be taken with or without food. Azithromycin is extensively distributed throughout the body, with a mean steady‑state volume of distribution of 31.1 L/kg. It achieves particularly high and sustained concentrations in phagocytes, including neutrophils and alveolar macrophages, which transport the drug to sites of infection. Tissue concentrations can be 10‑ to 100‑fold higher than concurrent plasma concentrations, a property that underpins its efficacy with short treatment courses. The drug is eliminated primarily via biliary excretion as unchanged drug and metabolites, with a small fraction excreted renally. The terminal elimination half‑life is approximately 68 hours, which allows once‑daily dosing and persistent therapeutic concentrations for several days after the last dose. Azithromycin is a substrate of P‑glycoprotein (P‑gp) and is not significantly metabolized by cytochrome P450 enzymes, although it can inhibit CYP3A4 to a modest degree.

Indications

• Upper and Lower Respiratory Tract Infections: Pharyngitis and tonsillitis caused by Streptococcus pyogenes (as second‑line therapy in patients who cannot use penicillin); acute bacterial exacerbations of chronic obstructive pulmonary disease caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae; community‑acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Chlamydia pneumoniae in patients suitable for oral therapy.
• Uncomplicated Skin and Skin Structure Infections: Caused by Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae.
• Genitourinary Tract Infections: Urethritis and cervicitis due to Neisseria gonorrhoeae or Chlamydia trachomatis; genital ulcer disease in men due to Haemophilus ducreyi (chancroid).
• Prevention of Disseminated Mycobacterium Avium Complex (MAC) Disease: In persons with advanced HIV infection, azithromycin 1200 mg once weekly, alone or in combination with rifabutin.
• Acute Otitis Media (paediatric): Caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. The 100 mg/5 mL oral suspension is used for this indication.
• Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as cystic fibrosis, nosocomial infections, known or suspected bacteremia, hospitalization, elderly or debilitated status, or significant underlying health problems.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: Azithromycin should be used during pregnancy only if clinically needed and the benefit is expected to outweigh any potential risk to the fetus. A large amount of data from observational studies does not suggest an association with major congenital malformations or cardiovascular malformations; however, there is limited epidemiological evidence of an increased risk of miscarriage following azithromycin exposure in early pregnancy. Azithromycin crosses the placenta and distributes to fetal tissue.
• Breastfeeding: Azithromycin is excreted in human breast milk at an estimated highest median daily dose of 0.1 to 0.7 mg/kg/day. No serious adverse effects on breastfed infants have been observed, but the safety of azithromycin has not been studied in infants less than 6 months of age. If a lactating mother is treated with azithromycin, the breast milk should be expressed and discarded during treatment. A decision must be made whether to discontinue breastfeeding or to discontinue the drug.
• Paediatrics: The safety and efficacy of azithromycin have been established for specific indications in children. Dosing is weight‑based. The 10 mg/kg once‑daily regimen is commonly used, and the 100 mg/5 mL oral suspension is typically prescribed. Azithromycin is not recommended for infants under 6 months of age except under specialist guidance.
• Elderly: No dose adjustment is required for elderly patients with normal renal and hepatic function. However, elderly patients may be more susceptible to the development of torsade de pointes arrhythmias (see Cardiovascular below).
• Cardiovascular — QT Prolongation: Macrolide antibiotics, including azithromycin, can prolong cardiac repolarization and the QT interval, imparting a risk of developing cardiac arrhythmia and torsade de pointes, which can be fatal. Prescribers should consider this risk when weighing the benefits and risks. Risk factors include a history of torsade de pointes, congenital or documented QT prolongation, concomitant use of drugs known to prolong the QT interval, electrolyte disturbance (particularly hypokalaemia and hypomagnesaemia), clinically relevant bradycardia, cardiac arrhythmia, cardiac insufficiency, and advanced age.
• Hepatic impairment: Azithromycin is contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior azithromycin use. Since the liver is the principal route of elimination, azithromycin should be used with caution in patients with impaired hepatic function. Rare cases of hepatic necrosis requiring liver transplant or causing death have been reported. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur.
• Renal impairment: No dosage adjustment is required for patients with a glomerular filtration rate (GFR) of 10‑80 mL/min. Caution should be exercised in patients with GFR < 10 mL/min due to increased systemic exposure and a higher incidence of gastrointestinal adverse events.
• Myasthenia gravis: Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients receiving azithromycin therapy. The use of azithromycin in patients with a known history of myasthenia gravis is not recommended.
• Hypersensitivity: Serious and sometimes fatal allergic reactions, including angioedema, anaphylaxis, and severe cutaneous adverse reactions such as Acute Generalized Exanthematous Pustulosis (AGEP), Stevens‑Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported. If an allergic reaction occurs, the drug should be discontinued and appropriate therapy instituted. Physicians should be aware that reappearance of allergic symptoms may occur when symptomatic therapy is discontinued.
• Clostridioides difficile‑associated disease (CDAD): CDAD has been reported with the use of many antibacterial agents, including azithromycin, and may range in severity from mild diarrhoea to fatal colitis. CDAD can occur more than 2 months after the administration of antibacterial agents.
• Ergot derivatives: Azithromycin and ergot derivatives should not be co‑administered due to the possibility of ergot toxicity, characterised by severe peripheral vasospasm, dysesthesia, and possible central nervous system effects.
• Lactose intolerance: Due to the lactose content in the tablet coating, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose‑galactose malabsorption should not take the tablet formulation.
• Allergy: Do not take Zithromax if you have a known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibacterial agent, or any excipient in the formulation.

Driving and alcohol

Azithromycin is not generally expected to impair the ability to drive or operate machinery. However, some patients may experience dizziness or headache, particularly at the start of therapy. Patients should ensure they are not adversely affected before driving or engaging in hazardous activities. Alcohol consumption should be limited during treatment because it can worsen gastrointestinal side effects such as nausea and diarrhoea, impair the immune response, and dehydrate the body. Heavy alcohol consumption, especially when combined with other risk factors, may increase the potential for hepatotoxicity.

Dosage Instructions

• Upper and lower respiratory tract infections, skin and skin structure infections (adults): The recommended dose is 500 mg as a single dose on the first day, followed by 250 mg once daily on days 2 through 5, for a total dose of 1.5 grams. Alternatively, for acute bacterial exacerbations of COPD and acute bacterial sinusitis, 500 mg once daily for 3 days may be used.
• Genitourinary infections — Chlamydia trachomatis: A single 1 gram (1000 mg) oral dose, administered as four 250 mg tablets, two 500 mg tablets, or the 1 gram single‑dose sachet.
• Genitourinary infections — Neisseria gonorrhoeae: A single 2 gram (2000 mg) oral dose.
• Genital ulcer disease (chancroid): A single 1 gram (1000 mg) oral dose.
• Prevention of disseminated MAC disease: 1200 mg (two 600 mg tablets) taken once weekly, which may be continued with the approved dosage regimen of rifabutin.
• Paediatric dosing: Acute otitis media: 30 mg/kg as a single dose, or 10 mg/kg once daily for 3 days, or 10 mg/kg as a single dose on day 1 followed by 5 mg/kg on days 2 through 5. Community‑acquired pneumonia: 10 mg/kg as a single dose on day 1, followed by 5 mg/kg once daily on days 2 through 5. Pharyngitis/tonsillitis: 12 mg/kg once daily for 5 days. The oral suspension (100 mg/5 mL or 200 mg/5 mL) is used for children according to weight.
• Administration: Azithromycin immediate‑release tablets can be taken with or without food. The tablets should be swallowed whole with a full glass of water. Do not crush, chew, or split the tablets. The oral suspension should be shaken well before each use and measured with the calibrated dosing device provided by the pharmacy. The single‑dose 1 gram sachet should be mixed with water and taken immediately.
• Missed dose: If a dose is missed, take it as soon as remembered on the same day. If it is close to the time of the next scheduled dose, skip the missed dose and continue with the regular schedule. Do not double the dose to make up for a missed one.
• Completion of therapy: Complete the full prescribed course of antibiotic therapy, even if symptoms improve earlier. Stopping treatment prematurely can lead to a return of the infection and promote the development of antibiotic resistance.

Side Effects and Contraindications

• Most common side effects (incidence ≥ 1% in clinical trials): Diarrhoea or loose stools (4‑5%), nausea (3‑4%), abdominal pain (2‑3%), vomiting (1‑2%), headache, dizziness, and skin rash. With the single 1‑gram dose, the incidence of gastrointestinal side effects is higher: diarrhoea (6.1%), nausea (4.9%), and abdominal pain (4.9%). With the single 2‑gram dose, nausea (18.2%), diarrhoea/loose stools (13.8%), vomiting (6.7%), and abdominal pain (6.7%) are more common.
• Less common side effects (incidence ≤ 1%): Dry mouth, esophagitis, gastroenteritis, rectal haemorrhage, pruritus, hypertension, dizziness, conjunctivitis, menorrhagia, urinary frequency, and vaginitis.
• Serious adverse reactions: QT interval prolongation and torsade de pointes (which may be fatal); hepatotoxicity, including abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure (some cases requiring liver transplant or resulting in death); Clostridioides difficile‑associated diarrhoea (ranging from mild diarrhoea to fatal pseudomembranous colitis); serious allergic reactions including angioedema, anaphylaxis, Acute Generalized Exanthematous Pustulosis (AGEP), Stevens‑Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS); exacerbation of myasthenia gravis; and severe neutropenia.
• Post‑marketing reports: Pancreatitis, interstitial nephritis, acute renal failure, thrombocytopenia, and hearing loss or tinnitus have been reported in rare cases.
• Contraindications: Hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic, or any excipient in the formulation. History of cholestatic jaundice or hepatic dysfunction associated with prior azithromycin use. Concomitant use with ergot derivatives.

Drug Interactions

• Ergot derivatives — contraindicated: Co‑administration of azithromycin with ergotamine, dihydroergotamine, or other ergot derivatives may precipitate acute ergot toxicity, characterised by severe peripheral vasospasm, dysesthesia, and possible central nervous system effects. This combination should be avoided.
• Antacids — moderate interaction: Aluminum‑ and magnesium‑containing antacids reduce the peak plasma concentration of azithromycin by approximately 25% when administered simultaneously. Azithromycin should be taken at least 1 hour before or 2 hours after antacids.
• QT‑prolonging drugs — major interaction (avoid or monitor closely): Concomitant use of azithromycin with other drugs that prolong the QT interval—such as Class IA and III antiarrhythmics, antipsychotics, tricyclic antidepressants, fluoroquinolones, and some antifungal agents—significantly increases the risk of torsade de pointes and cardiac arrest. These combinations should be avoided when possible; if unavoidable, ECG monitoring is recommended.
• Warfarin — moderate interaction: Azithromycin may potentiate the anticoagulant effect of warfarin. Although a dedicated drug interaction study showed no effect on the prothrombin time, post‑marketing reports of increased anticoagulation have been observed. Close monitoring of the International Normalised Ratio (INR) is recommended during and for several days after concurrent therapy.
• Digoxin — moderate interaction: Macrolide antibiotics may increase the absorption and serum concentrations of digoxin by inhibiting P‑glycoprotein, potentially leading to digoxin toxicity. Serum digoxin levels should be monitored.
• Cyclosporine — moderate interaction: Azithromycin may increase cyclosporine serum concentrations. Monitor cyclosporine levels and adjust the dose as necessary.
• Nelfinavir — moderate interaction: Nelfinavir increases the area under the curve (AUC) of azithromycin by approximately 100%. No dose adjustment of azithromycin is recommended when used for short‑term therapy, but the patient should be monitored for side effects such as hearing loss or liver enzyme elevations.
• Theophylline — minor interaction: Although some macrolides are known to reduce theophylline clearance, azithromycin appears to have a lower propensity for this interaction. However, monitoring of serum theophylline levels is recommended when co‑administered.
• Statins — minor interaction: There are isolated reports of rhabdomyolysis in patients receiving azithromycin with certain statins. Caution is advised.

Practical Advice

• Administration: Take Zithromax tablets with a full glass of water. They may be taken with or without food; if stomach upset occurs, taking the medication with food may reduce gastrointestinal discomfort. Do not crush, chew, or split the tablets. Take the medication at approximately the same time each day. Complete the full prescribed course of therapy, even if you feel better after a few days. Stopping the antibiotic too early may allow the bacteria to continue to grow, which may result in a return of the infection and increase the risk of antibiotic resistance. For the oral suspension, shake well and measure with the provided dosing spoon or syringe.
• Monitoring: No routine laboratory monitoring is required for most patients. In patients with pre‑existing liver disease or those who develop symptoms of hepatitis (jaundice, dark urine, right upper abdominal pain, unexplained fatigue), liver function tests should be monitored. ECG monitoring may be considered for patients at risk of QT prolongation. INR should be monitored more frequently in patients taking warfarin.
• Storage: Store tablets at room temperature (15‑30 °C) in a dry place, protected from moisture and light. Keep the tablets in their original packaging. Store the oral suspension at room temperature and discard any unused portion after 10 days. Keep out of the reach and sight of children.
• Lifestyle: Take this medication exactly as directed by your healthcare professional. Do not share this antibiotic with anyone else, even if they have similar symptoms. If you experience diarrhoea that is watery or bloody, contact your doctor before using any anti‑diarrhoeal product. Drink plenty of fluids to prevent dehydration. Limit alcohol intake during treatment.
• Missed dose: If you miss a dose, take it as soon as you remember on the same day. If it is almost time for your next dose, skip the missed dose and return to your regular schedule. Do not take two doses at once.
• When to seek medical review: Contact your doctor immediately if you develop signs of liver injury (yellowing of the skin or eyes, dark urine, right upper abdominal pain, unexplained fatigue); signs of a serious allergic reaction (hives, difficulty breathing, swelling of the face, lips, tongue, or throat, severe rash or blistering of the skin); severe, persistent diarrhoea (watery or bloody); palpitations, fainting, or a rapid or irregular heartbeat; or muscle weakness or difficulty breathing (possible worsening of myasthenia gravis). Seek emergency medical attention immediately for any of these symptoms. An overdose may cause reversible hearing loss, severe nausea, vomiting, and diarrhoea; contact a poison control centre or seek emergency care if an overdose is suspected.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Clarithromycin (Biaxin®): Another macrolide antibiotic with a similar spectrum of activity. Clarithromycin requires twice‑daily dosing and has a shorter half‑life than azithromycin, but it is also available as an extended‑release formulation. It is more likely to interact with cytochrome P450 enzymes and has a higher potential for drug interactions.
• Erythromycin: The original macrolide antibiotic, available in multiple oral formulations. Erythromycin requires three to four times daily dosing, is more likely to cause gastrointestinal side effects, and has a higher potential for serious drug interactions, including with statins and calcium channel blockers. It is now rarely used as a first‑line agent.
• Doxycycline (Vibramycin®): A tetracycline antibiotic that is the first‑line oral treatment for chlamydial infections (100 mg twice daily for 7 days) and many respiratory infections. It shares no cross‑resistance with macrolides and is a suitable alternative for penicillin‑allergic patients. It should not be used in children under 8 years of age or during pregnancy.
• Amoxicillin (Amoxil®): A penicillin‑class antibiotic that is the first‑line agent for streptococcal pharyngitis and many respiratory and ear infections. It is often preferred when culture and sensitivity results confirm susceptibility, and it is the drug of choice for the prevention of rheumatic fever. It has a different safety profile and is generally well tolerated.
• Amoxicillin‑clavulanate (Clavulin®): A penicillin‑beta‑lactamase inhibitor combination that provides broader coverage, including against beta‑lactamase‑producing strains of Haemophilus influenzae and Moraxella catarrhalis. It is an alternative to azithromycin for respiratory tract infections in areas with high rates of macrolide resistance.
• Levofloxacin or Moxifloxacin (respiratory fluoroquinolones): These are reserved for more severe respiratory infections or when first‑line agents have failed. They have broad‑spectrum activity but carry a risk of serious adverse effects including tendinitis, tendon rupture, peripheral neuropathy, and QT prolongation. They are not first‑line for mild to moderate infections.
• Non‑pharmacological measures: Rest, adequate hydration, and symptomatic management with analgesics and antipyretics are important supportive measures for bacterial infections. For pharyngitis, gargling with warm salt water can provide symptomatic relief. For sinusitis, nasal saline irrigation and steam inhalation may help relieve congestion.

Clinical Efficacy

The clinical efficacy of azithromycin has been established in numerous randomized, double‑blind, placebo‑controlled and active‑comparator clinical trials across a wide range of bacterial infections. In the treatment of community‑acquired pneumonia, azithromycin 500 mg once daily (with 500 mg on day 1 and 250 mg on days 2‑5) produced clinical cure rates of 90‑95%, comparable to those achieved with amoxicillin‑clavulanate, clarithromycin, and levofloxacin. In acute bacterial exacerbations of COPD, azithromycin 500 mg daily for 3 days was as effective as 5‑day courses of alternative antibiotics. For streptococcal pharyngitis, azithromycin 12 mg/kg daily for 5 days (paediatric) or 500 mg on day 1 and 250 mg on days 2‑5 (adult) produced bacterial eradication rates of approximately 90‑94%.

For genitourinary infections, a single 1 gram oral dose of azithromycin is highly effective against Chlamydia trachomatis, with microbiological cure rates exceeding 95%. Azithromycin has been a cornerstone of chlamydia treatment for decades, although current Canadian guidelines now recommend doxycycline 100 mg twice daily for 7 days as first‑line therapy for uncomplicated genital chlamydia in non‑pregnant adults, reserving azithromycin for pregnant women and patients in whom adherence to a 7‑day course cannot be ensured. For gonococcal infections, a single 2 gram dose of azithromycin is effective, but because of rising resistance, Health Canada and international guidelines now recommend that azithromycin be used only in combination with ceftriaxone for the treatment of gonorrhoea, or not at all when alternative regimens are available.

The immunomodulatory properties of azithromycin have been exploited for the long‑term management of chronic respiratory diseases. In the AZISAST, COLUMBUS, and EMBRACE trials, long‑term, low‑dose azithromycin (250 mg or 500 mg three times weekly) significantly reduced the frequency of exacerbations in patients with COPD, bronchiectasis, and cystic fibrosis. The mechanism is believed to involve the drug’s anti‑inflammatory effects and its ability to reduce biofilm formation by Pseudomonas aeruginosa and other pathogens. The Canadian Thoracic Society guidelines recommend long‑term macrolide therapy as an option for patients with frequent COPD exacerbations despite optimal inhaled therapy.

The pharmacokinetic properties of azithromycin—particularly its extensive tissue distribution and long elimination half‑life—make it uniquely suited to short‑course and single‑dose regimens. The 3‑day regimen of 500 mg once daily and the single 1 gram and 2 gram doses have been demonstrated to be clinically equivalent to longer courses of other antibiotics in head‑to‑head trials. These short courses improve patient adherence and reduce the total antibiotic exposure, which may contribute to antimicrobial stewardship. However, resistance to macrolides, particularly among Streptococcus pneumoniae and Streptococcus pyogenes, is a growing concern. In Canada, macrolide resistance rates among S. pneumoniae range from 15% to 30%, and clinicians are advised to consider local resistance patterns when choosing an empiric antibiotic for respiratory infections.

Important:

Zithromax (azithromycin) is a prescription antibiotic that should be used only under the supervision of a qualified healthcare professional. It is intended to treat bacterial infections only and is not effective against viral infections such as the common cold or flu. Take the full prescribed course of this medication, even if your symptoms improve earlier. Azithromycin can cause a change in the electrical activity of the heart (QT prolongation), which can lead to serious (rarely fatal) fast/irregular heartbeat and other symptoms, such as severe dizziness and fainting, requiring immediate medical attention. The risk is increased in elderly patients, those with a history of heart rhythm problems, and those taking other QT‑prolonging medications. Rare but serious liver injury has been reported; discontinue azithromycin immediately and contact your doctor if you develop signs of hepatitis (jaundice, dark urine, right upper abdominal pain, unexplained fatigue). Serious allergic reactions, including severe skin reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis), have been reported. If you experience hives, difficulty breathing, or swelling of the face, lips, tongue, or throat, stop taking the medication and seek emergency medical attention. Azithromycin is contraindicated in patients with a history of cholestatic jaundice or liver dysfunction associated with prior azithromycin use. Do not take this medication with ergotamine or dihydroergotamine (used to treat migraines). This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Zithromax - Shipping across Canada